Lab: Bladder/Urothelial Tumor Markers

Bladder/urothelial tumor marker tests (e.g., BTA, NMP-22, UroVysion, ImmunoCyt) are covered when used as adjuncts to cystoscopy for evaluation of suspected bladder cancer or for surveillance of patients with prior urothelial carcinoma. Markers are not covered for routine screening of all patients with hematuria or asymptomatic populations and should generally be ordered only after other diagnostic studies have failed to identify the cause of hematuria; several marker assays are considered investigational and not covered.

"Bladder/urothelial tumor marker testing is covered when performed in conjunction with cystoscopy to evaluate patients with signs or symptoms suggestive of bladder cancer (for initial diagnosis or e..."

Sign up to see full coverage criteria, indications, and limitations.